HSIC · Q2 2025 Earnings
CautiousHenry Schein
Reported August 5, 2025
30-second summary
Henry Schein maintained FY2025 non-GAAP EPS guidance of $4.80–$4.94 on 3.3% revenue growth to $3.24B, but the substance of the quarter was elsewhere: management engaged two outside consulting firms plus KKR's Capstone to fix distribution gross margins, framed 2025 as a "base year" rather than a growth year, and announced CEO Stanley Bergman's retirement at year-end. Dental merchandise growth was -0.4%, glove pricing remains a structural drag, and the payoff from new initiatives was explicitly deferred to "the beginning of 2026." Maintained guidance with a back-half weighting masks a company that is reorganizing under pressure.
Headline numbers
EPS
Q2 FY2025
$1.10
Revenue
Q2 FY2025
$3.24B
+3.3% YoY
Gross margin
Q2 FY2025
31.4%
Operating margin
Q2 FY2025
4.7%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $3.24B | +3.3% |
| EPS | $1.10 | — |
| Gross margin | 31.4% | — |
| Operating margin | 4.7% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Global Distribution and Value-Added Services | $2.731B | +2.9% |
| Global Specialty Products | $0.386B | +4.2% |
| Global Technology | $0.167B | +7.4% |
| Global Dental | $1.715B | +1.1% |
| Global Medical | $1.016B | +6.1% |
| U.S. Distribution and Value-Added Services | $1.86B | +2.2% |
| International Distribution and Value-Added Services | $0.871B | +4.5% |
| Global Dental merchandise sales growth | -0.4% | — |
| Global Medical sales growth | +6.1% | — |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Adjusted EBITDA | $256 million |
| Internal sales growth | 1.9% |
| Acquisition sales growth | 0.8% |
| FX impact on sales | +0.6% |
| Specialty Products implant and biomaterial sales | Growing |
| Technology cloud-based solutions (Dentrix Ascend, Dentally) | Strong growth |
Management tone
Henry Schein has historically presented itself as a self-directed operator with internal capability to manage its margin profile. Three notable shifts surfaced this quarter, all pointing the same direction.
The margin fix is being outsourced. Management disclosed it has engaged two leading global management consulting firms to address distribution gross margins, on top of the KKR Capstone partnership. The verbatim framing — "We have engaged two leading global management consulting firms to support our efforts to enhance distribution gross margins" — is a meaningful departure for a company that has long emphasized operational autonomy. It signals that internal levers have been exhausted and that the structural pressure from glove pricing and competitive distribution dynamics is not self-correcting.
The recovery timeline has slipped to 2026. Management explicitly stated that "2025 to be the base year from which to grow" and that the consulting-led projects "start producing results towards the beginning of 2026." This reframes 2025 from a recovery year — which is how a maintained EPS guide of $4.80–$4.94 might otherwise read — to a foundation year. The long-term high-single-digit to low-double-digit earnings growth aspiration is now a 2026+ goal, not a 2025 trajectory.
Leadership transition lands at the same moment. CEO Stanley Bergman announced his retirement at year-end, transitioning to chairman, with Andrea Albertini and Tom Popek taking expanded roles. CEO succession concurrent with a strategic reset and an external consultant engagement compounds execution risk into 2026, even if the maintained guidance line is intended to project continuity.
Glove pricing has moved from temporary to structural. Earlier framing treated lower glove pricing as a transient promotional/competitive issue. This quarter, management responded to it by "accelerating sales of our owned products portfolio" and engaging consultants — a strategic, not tactical, response. Glove pressure is now a permanent feature of the distribution gross margin equation.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Jason Bednar · Piper Sandler
Asked about July merchandise sales momentum without above-normal promotions, patient traffic, spending confidence, and customer conversations around tariff-driven price increases and margin protection.
July trends are positive with strong customer momentum. Patient traffic is relatively stable globally, particularly in served markets. Tariffs are being passed through to customers who understand the company cannot absorb them. Customers are shifting to Henry Schein's own brands and second-tier manufacturers to manage tariff impacts. Glove market remains competitive but company gains market share.
Jason Bednar · Piper Sandler
Follow-up on early-stage consulting engagement with outside firms and what cost/revenue opportunities have been identified alongside existing restructuring.
Over $100 million already achieved in restructuring. Two key initiatives with KKR/Capstone: (1) gross margin enhancement through owned brands and manufacturer partnerships targeting better customer deals and margin improvement; (2) SG&A management through global services optimization. Work started in Europe 5-6 months ago with good results, now rolling to U.S. Expecting good results in 2026 but not providing specific numbers yet. Emphasis on AI and structural opportunities.
Elizabeth Anderson · Evercore
Asked about EPS cadence in second half given back-half weighting in guidance, $25M bold plus one initiatives, and $75-100M restructuring savings.
Confirmed back-half weighting with Q3 EPS expected to grow and Q4 potentially exceeding Q3. July momentum and expanded distribution sales team expected to drive results. Dental equipment expected to show momentum in H2 supported by solid backlog. Specialty products and Tapered Pro-Conical continuing strong sequential growth. Restructuring providing cost savings. Remeasurement gains may add lumpiness to quarterly cadence.
Alan Lutz · Bank of America
Asked about gross margins in distribution business in H2 if returned to normal merchandise pricing, and whether Capstone gross margin initiatives should be viewed as accretive to prior-year baselines.
Glove pricing stabilized but will likely remain slightly lower than prior year due to market competition. Sequential stabilization expected in Q3. Overall margins benefit from strong technology and specialty products growth. Product mix and specialty growth will provide benefits but certain categories like gloves will continue pressure. Capstone initiatives focused on driving gross profit through value provision and margin enhancement.
John Stanzel · JPMorgan Chase
Asked to size targeted sales impact in Q2, what changed from Q1 call to pursue initiative, and comment on larger customer RFP activity and competitive balance.
Targeted sales initiative was a limited, customer-specific program aimed at win-back of customers who left during cyber incident or reduced purchases. Framed as 'frequent buyer' affinity program to fill 'hole in the bucket.' Program not intended for all customers, only select lapsed accounts. RFPs from larger customers are normal occurring every 3-4 years, not more aggressive than expected. Company retains customers through supply chain capabilities, service, owned brands, equipment, software offerings, and revenue cycle management benefits.
What to watch into next quarter
Distribution gross margin trajectory — Management said H2 distribution gross margins will be slightly below prior year despite initiatives. Watch whether Q3 segment gross margin compression is contained to glove-related pressure or widens into other categories. Any sequential margin deterioration would put the FY EPS midpoint of $4.87 at risk.
Quantified Capstone/KKR targets — Management committed to providing "mathematical targets" for the value creation initiatives. Watch whether Q3 brings specific 2026 EBITDA or gross-margin dollar contribution figures, or whether the targets continue to be deferred.
Q3 EPS growth confirmation — Management explicitly guided Q3 EPS to grow YoY with Q4 stronger. Q3 prints below the prior-year quarter would force a guidance cut given the $4.80 floor and ~$1.10 Q2 base.
Dental merchandise growth turn — Dental merchandise was -0.4% in Q2. Watch for a return to positive growth in Q3; sustained decline would invalidate the back-half-recovery narrative.
CEO transition disclosures — Bergman retires at year-end. Watch the Q3 call for clearer delineation of CEO successor authority (Albertini vs Popek vs continued committee structure) — ambiguity here heading into a strategic reset would be a negative signal.
Restructuring savings burn rate — $100M+ achieved year-to-date, $75–100M embedded in FY guide. Watch whether incremental Q3/Q4 savings exceed the implied run rate, which would create EPS upside, or fall short, which would force reliance on revenue acceleration that the segment data does not support.
Sources
- Henry Schein Q2 2025 press release, Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/1000228/000100022825000042/exhibit991.htm
- Henry Schein Q2 2025 earnings call (analyst commentary and management responses, sourced from call transcript references in extraction)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.